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Clinics 
Age and sex: 81 years old male patient. 
Previous History : no preleukemia ;  no inborn 
condition of note. 
Organomegaly : no hepatomegaly ; no splenomegaly ; 
enlarged lymph nodes ; no central nervous system 
involvement. 
Blood 
WBC: 3.3 x 109/l; Hb: N/A g/dl; platelets: 16x 109/l; 
blasts: 2% (CD34+ myeloblasts). 
Bone marrow: 20% myeloid precursors, 16% erythroid 
precursor, 6% lymphocytes, 55% blasts and 2% plama 
cells. 
Cytopathology classification 
Cytology: AML M0 
Immunophenotype: CD33+, CD13+, MPO-, CD41-, 
CD61-, CD203c- (5% of all blast). 
Rearranged Ig or Tcr: N/A 
Precise diagnosis: Immunophenotype consistent with 
the presence of myeloid precursors. Negative markers 
(CD61,CD41,CD203c) associated with megakaryocytic 




Date of diagnosis: 01-2005. 
Treatment: Hydroxyurea and supportive care. 
Complete remission: None 
Treatment related death: - 
Relapse: Patient never achieved complete remission. 
Status: Dead 02-2005. 
Survival: 1 months. 
Karyotype 
Sample: Bone marrow; Culture time: 24h; Banding: 
GTG. 
Results: 46,XY,t(1;21)(p36;q22)[15] 
Other molecular cytogenetic technics: FISH with LSI 
(TEL/AML1 ES Dual Color Translocation Probe 
(Vysis, Inc.) on metaphases (see Fig 2). 
Other molecular cytogenetics results: Ish 
der(1)(dimAML1+), der(21)(dimAML1+). 
Comments 
The t(1;21)(p36;q22) so far reported, is generally 
observed as the sole chromosomal abnormality (5/6), 
and is mostly a de novo aberration (4/6). The short 
survival (one month) of our case, confirms the poor 
prognosis in these patients carrying this chromosome 
abnormality. 
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Partial GTG-banding karyotype showing t(1;21)(p36;q22)) (a) 
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